Physician profile
Sarabdeep S Mann
NPI 1508283706
$16,024.97
in general payments reported to CMS, 2019-2025
41 companies · $4,592 in 2025
The $4,592 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $234 · 2021: $605 · 2022: $2,694 · 2023: $3,593 · 2024: $3,735 · 2025: $4,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,778.61 |
| Education | $142.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,551.30 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,820.57 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $1,556.65 | 2019-2025 | |
| Janssen Biotech, INC. | $1,340.32 | 2022-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,225.97 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Phathom Pharmaceuticals, INC. | $684.41 | 2023-2025 | Voquezna |
| Celgene Corporation | $398.86 | 2022-2024 | Zeposia |
| Celltrion USA INC. | $372.42 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Ipsen Biopharmaceuticals, INC | $364.34 | 2024-2025 | Iqirvo |
| Lilly USA, LLC | $345.97 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $309.42 | 2022-2025 | Ibsrela |
| Conmed Corporation | $289.93 | 2019 | |
| Genzyme Corporation | $280.75 | 2023-2025 | |
| Merit Medical Systems INC | $265.99 | 2025 | Esophyx |
| Ferring Pharmaceuticals INC. | $265.42 | 2021-2024 | Rebyota, Clenpiq |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $196.30 | 2022-2025 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $185.83 | 2022-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $180.44 | 2023-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $179.43 | 2022-2023 | |
| Gilead Sciences, INC. | $165.27 | 2021-2022 | |
| Madrigal Pharmaceuticals | $135.65 | 2024-2025 | Rezdiffra, Resmetirom |
| Organon LLC | $132.31 | 2022-2024 | Renflexis, Hadlima |
| E.R. Squibb & Sons, L.L.C. | $121.84 | 2021 | |
| Biocon Biologics INC | $101.10 | 2024-2025 | Yesintek, Hulio |
| Qol Medical, LLC | $70.73 | 2023-2024 | Sucraid, Sucraid |
| Redhill Biopharma INC. | $62.91 | 2021-2022 | |
| Medtronic, INC. | $55.59 | 2025 | Gi Genius |
| Lucid Diagnostics INC. | $42.89 | 2021 | |
| Amgen INC. | $42.13 | 2023 | Amjevita, Avsola |
| Boston Scientific Corporation | $37.02 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.68 | 2023-2024 | Cyltezo |
| Janssen Scientific Affairs, LLC | $35.30 | 2020 | |
| Fresenius Kabi USA, LLC | $33.84 | 2023 | Idacio |
| Laborie Medical Technologies Corp. | $32.68 | 2024-2025 | Solar Uroflow System |
| Novo Nordisk INC | $23.27 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $19.59 | 2024 | |
| Merck Sharp & Dohme LLC | $14.77 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $14.07 | 2025 | |
| Alnylam Pharmaceuticals INC. | $14.00 | 2023 | Amvuttra |
| Digestive Care, INC. | $11.80 | 2025 | Pertzye |
| Intra-Sana Laboratories | $7.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarabdeep Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.